BioPharma Resources

Drug Trial Radar · NCT07691970

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,072

Planned (sponsor's estimate)

Start

Aug 31, 2026

Primary completion

Dec 30, 2032

Study completion Dec 30, 2032

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 5 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability. Study details include: * Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study. * The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study. * The participants will continue to receive anifrolumab the same way they received it in the parent trial * A participant is considered to have completed the study when they meet one of the discontinuation criteria. * Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.

Conditions

  • Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

Interventions

  • AnifrolumabCombination product

    Anifrolumab pre-filled syringe

  • AnifrolumabCombination product

    Anifrolumab solution for injection in pre-filled pen

  • AnifrolumabDrug

    Anifrolumab concentrate for solution for infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SAEs and Non-Serious AEsTime frame: From first dose administered and until 12 weeks after the last dose of Anifrolumab

Locations

166 sites in 35 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona · Not yet recruiting

  • Research Site

    Irvine, California · Not yet recruiting

  • Research Site

    Los Angeles, California · Recruiting

  • Research Site

    San Francisco, California · Not yet recruiting

  • Research Site

    Boca Raton, Florida · Recruiting

  • Research Site

    Fort Lauderdale, Florida · Recruiting

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Indianapolis, Indiana · Not yet recruiting

  • Research Site

    Baltimore, Maryland · Not yet recruiting

  • Research Site

    Boston, Massachusetts · Not yet recruiting

  • Research Site

    Ann Arbor, Michigan · Not yet recruiting

  • Research Site

    Rochester, Minnesota · Not yet recruiting

  • Research Site

    Omaha, Nebraska · Not yet recruiting

  • Research Site

    New York, New York · Not yet recruiting

  • Research Site

    Charlotte, North Carolina · Recruiting

  • Research Site

    Cleveland, Ohio · Not yet recruiting

  • Research Site

    Columbus, Ohio · Not yet recruiting

  • Research Site

    Portland, Oregon · Not yet recruiting

  • Research Site

    Charleston, South Carolina · Not yet recruiting

  • Research Site

    Dallas, Texas · Not yet recruiting

  • Research Site

    Roanoke, Virginia · Not yet recruiting

  • Research Site

    Quilmes, Argentina · Not yet recruiting

  • Research Site

    San Miguel, Argentina · Not yet recruiting

  • Research Site

    Melbourne, Australia · Not yet recruiting

  • Research Site

    Mitcham, Australia · Not yet recruiting

  • Research Site

    Westmead, Australia · Not yet recruiting

  • Research Site

    Graz, Austria · Not yet recruiting

  • Research Site

    Graz, Austria · Not yet recruiting

  • Research Site

    Linz, Austria · Not yet recruiting

  • Research Site

    Vienna, Austria · Not yet recruiting

  • Research Site

    Ghent, Belgium · Not yet recruiting

  • Research Site

    Leuven, Belgium · Not yet recruiting

  • Research Site

    Belo Horizonte, Brazil · Not yet recruiting

  • Research Site

    Porto Alegre, Brazil · Not yet recruiting

  • Research Site

    Rio de Janeiro, Brazil · Not yet recruiting

  • Research Site

    Salvador, Brazil · Not yet recruiting

  • Research Site

    São Paulo, Brazil · Not yet recruiting

  • Research Site

    Haskovo, Bulgaria · Not yet recruiting

  • Research Site

    Plovdiv, Bulgaria · Not yet recruiting

  • Research Site

    Sofia, Bulgaria · Not yet recruiting

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.